Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

[Prøvning af enhed, der ikke er godkendt eller godkendt af U.S. FDA]

16. november 2026 opdateret af: BrainQ Technologies Ltd.

This is a multicenter study that will be conducted at approximately 20 centers and up to 30 centers, if the sample size will be increased following interim assessment.

The Q Therapeutic System (BQ 3.0) is a wearable medical device that produces and delivers non-invasive, extremely-low-intensity and low-frequency, frequency-tuned electromagnetic fields in order to stimulate neuronal networks with the aim of reducing disability and promoting neurorecovery.

The Q Therapeutic System (BQ 3.0) is indicated for adjunctive use in a clinical facility or home setting, in addition to standard-of-care therapies.

  • In Stage 1 (starting 4-21 days after the index stroke event to day 90 post stroke), participants will be randomly assigned (1:1) to receive either active or the sham treatments, up to 5 times a week, and at least to a total of 45 treatments.
  • In Stage 2 (day 90 to day 180 post stroke), participants in both the active and the control group will be allowed to continue to receive active treatments, up to 5 times per week.
  • In stage 3 (day 180 to day 270 post stroke), participants will not receive any treatments and would be followed up until the final visit at day 270.

Each session will last approximately 60 minutes, with stimulation activated for up to 40 minutes, in conjunction with a home-based exercise program. Treatments may be administered in the hospital, in the clinic or in a home setting.

The study will enroll 100-122 adult subjects who will be randomly assigned (1:1 allocation ratio) to either active or sham study intervention using the BQ 3.0 system.

Studieoversigt

Detaljeret beskrivelse

The study intervention will be initiated 4-21 days after the index stroke event and will consist of 5 treatments per week until the primary endpoint follow-up visit, at day 90 (±15) after the onset of the index stroke. A minimum of 45 treatment sessions should be completed during this stage, with a potential of a maximum of 72 treatment sessions, depending on the start date of the first treatment and the timing of the 90-day follow-up visit. Though, participants and sites will be guided to conduct the 90 days follow-up visit as soon as possible after the 45th treatment session and within up to 7 days from the 45th treatment and after the window opening.

Each treatment session will last approximately 60 minutes and include 40 minutes of active or sham stimulation. Subjects in both groups will be asked to perform a home-based exercise program for the upper and the lower limb, concurrent with the study intervention.

Screening phase:

Prospective subjects, who are 3 to 21 days post-stroke, may be offered informed consent to participate in the study at either:

a participating inpatient or outpatient center, non-participating inpatient or outpatient center, in accordance with both the participating and the non-participating centers' policy, or home Consented subjects, who are 4 to 21 days post-stroke, will be screened for eligibility to participate in the treatment phase of the study.

Eligible subjects will be randomly assigned, at a 1:1 allocation ratio, to either the active or sham study intervention groups.

Stimulation with the Q Therapeutic System (BQ 3.0) does not produce any noticeable sound, light, or tactile sensation which could disclose the treatment arm assignment, making this device ideal for testing in a sham-controlled design. During sham treatment sessions, for purposes of maintaining the blind, the device will function as if it is delivering the therapy (i.e., the device will turn on and all indicators will function), but the frequency and intensity parameters, which are not visible to the subject or site study members (or any blinded personnel), will be set to zero so that no stimulation is delivered.

Stage 1 (day 4 to day 90 (±15) post-stroke) - double-blind sham-controlled:

Efforts should be made to initiate the 1st treatment as early as possible within the window of recruitment, and target to complete a first treatment within 6 days from admission to a participating IRF (where applicable). The study intervention will be initiated 4-21 days after the index stroke event and will consist of 5 treatments per week until the primary endpoint follow-up visit, at day 90 (±15) after the onset of the index stroke. Each treatment session will last approximately 60 minutes and include 40 minutes of active or sham stimulation. Subjects in both groups will be asked to perform a home- based exercise program for the upper and the lower limb, concurrent with the study intervention. The program will be standardized, pre-defined, home-based, and aligned with standard-of-care1.

The participant and their caregiver will be trained on the use of the device and exercise program. Treatment sessions will be completed by the subject with the assistance of a trained caregiver, as needed. Periodic supervision will be provided by the study team (combined audio and video remote conferencing or audio only, if video is not available). A sponsor's representative may provide in-person or remote technical support to the participant and their caregiver, as well as device training, as needed.

Subjects will undergo a detailed interim outcome assessment on the 45th (±4) day after the onset of the index stroke, and a detailed primary endpoint outcome assessment on the 90th (±15) day after the onset of the index stroke. In addition, a focused, long-term outcome assessment on the 180th (±15) day after the onset of the index stroke will be performed.

Stage 2 (day 90 (±15) to day 180 (±15) post-stroke) - open-label:

Subjects in both the active and the sham groups (active /sham), who were adherent to the treatment in Stage 1 (defined as at least 35 completed treatment sessions in Stage 1) will be allowed to continue to receive active EMFstimulation treatments (i.e., with the electromagnetic therapy turned on).

Up to 5 active treatments per week will be completed, starting following the primary endpoint assessment follow-up visit at 90 (±15) days after the onset of the index stroke and continuing until the follow-up visit at 180 (±15) days after the onset of the index. Technically, a maximum of 86 treatment sessions can be completed during stage 2, depending on the timing of the 90-day and 180-day follow-up visits.

The blind, with respect to the group allocation in Stage 1, would be maintained for all parties (participants, investigators, assessors and Sponsor) until the trial completion and database lock.

Each session will last approximately 60 minutes and include 40 minutes of active stimulation. Subjects will be asked to perform a home-based exercise program, concurrent with the study intervention.

Treatment sessions will be completed by the subject with the assistance of a trained caregiver, as needed. Periodic supervision will be provided by the study team (combined audio and video remote conferencing or audio only, if video is not available). A sponsor's representative willmay provide in-person or remote technical support to the participant and their caregiver, as well as device training, as needed.

All subjects, including those who decided not to continue to receive treatments in Stage 2, will undergo a detailed follow-up assessment on the 180th (±15) day after the onset of the index stroke.

Stage 3 (day 180 (±15) to day 270 (±15) post-stroke):

At this Stage, no treatments sessions will take place. All subjects, including those who decided not to continue to receive treatments in Stage 2, will undergo In addition, aa focused, long-term outcome assessment on the 180th 270th (±15) day after the onset of the index stroke will be performed.

Any adverse events and device deficiencies occurring during the period of subject's participation in the trial will be recorded.

Participation in the study will not replace any of the usual care patient should receive.

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

62

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • California
      • Downey, California, Forenede Stater, 90242
        • Rancho Research Institute
    • District of Columbia
      • Washington D.C., District of Columbia, Forenede Stater, 20010
        • MedStar National Rehabililtaion Hospital,
    • Florida
      • Jacksonville, Florida, Forenede Stater, 32216
        • Brooks Rehabilitation Hospital
    • Georgia
      • Altanta, Georgia, Forenede Stater, 30322
        • Emory University School of Medicine
    • Illinois
      • Chicago, Illinois, Forenede Stater, 60611
        • Shirley Ryan AbilityLab
    • Kansas
      • Kansas City, Kansas, Forenede Stater, 66160
        • KUMC- KU Medical Center
    • New Jersey
      • Edison, New Jersey, Forenede Stater, 08818
        • Hackensack Meridian JFK Johnson Rehabilitation Institute
      • West Orange, New Jersey, Forenede Stater, 07052
        • Kessler Foundation for Rehabilitation
    • New York
      • Brooklyn, New York, Forenede Stater, 11215
        • New York-Presbyterian Brooklyn Methodist Hospital Inpatient Rehabilitation Unit
      • White Plains, New York, Forenede Stater, 10605
        • Burke Rehabilitation Hospital
    • North Carolina
      • Charlotte, North Carolina, Forenede Stater, 28203
        • Atrium Health Carolinas Rehabilitation
    • Pennsylvania
      • Elkins Park, Pennsylvania, Forenede Stater, 19027
        • Moss Rehabilitation Research Institute
    • Texas
      • Houston, Texas, Forenede Stater, 77030
        • UTHealth Houston
    • Wisconsin
      • Milwaukee, Wisconsin, Forenede Stater, 53226
        • Froedtert & Medical College of Wisconsin

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

22 år til 80 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  1. mRS score of 3 or 4.
  2. FMA-UE score between 10-45 (inclusive) of impaired limb.
  3. SAFE score >0.
  4. Age 22 to 80 years of age (inclusive).
  5. Diagnosed with an ischemic stroke, confirmed by CT4 or MRI5 imaging.
  6. First ever ischemic stroke, or a recurring ischemic stroke6 occurring at least 3 months after the previous stroke (any stroke), without residual neurological impairment or disability before current stroke.
  7. Four to 21 days from stroke onset (or last known well).
  8. Pre-stroke mRS of 0.
  9. Able to sit with the investigational device for 40 consecutive minutes, in the opinion of the investigator or designee.
  10. Can follow a 3-step command, such as "take the paper, fold it in half, and return it to me".
  11. Willingness to participate in an exercise activity during study intervention sessions.
  12. Availability of a relative or other caregiver able to assist in operating an application installed on a mobile device, including a video call, and assist the participant with the exercising program.
  13. If female, not pregnant (as confirmed by a urine or a blood test, or as determined by an official medical document) or breastfeeding and with no ability to become pregnant or on an acceptable method of contraception during the study
  14. Informed consent signed by subject.

Exclusion Criteria:

  1. Hemineglect impairment (NIHSS item 11, score >0).
  2. Implanted active electronic or passive MR-incompatible devices.
  3. Pre-existing major neurological condition (eg, Alzheimer's disease, Parkinson's disease, multiple sclerosis, traumatic brain injury, spinal cord injury) or pre-existing physical limitation that would interfere significantly with the subject's participation in the study and/or confound neurological or functional evaluation.
  4. Active epilepsy or currently taking anti-epileptic medication (indicated for the treatment of a seizure disorder), or any epileptic seizure in the last 5 years
  5. Significant visual disturbances, pre-existing or resulting from the index stroke, that cannot be corrected and that would interfere significantly with the subject's participation in the study and/or confound neurological or functional evaluation.
  6. Unstable serious illness/condition (eg, active cancer, severe heart failure, active major psychiatric condition) or life expectancy of less than 12 months.
  7. A known severe allergic reaction to acrylic-based adhesives.
  8. Alcohol abuse and/or illicit drug abuse in the past 6 months, which is likely to influence ability to fully participate in the trial.
  9. Participation in another trial that would conflict with the current study or clinical endpoint interference may occur.
  10. Employee of the Sponsor.
  11. Prisoner.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Støttende pleje
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Firedobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Sham-komparator: BQ 3.0 Sham Stimulation Group

Q Therapeutic System (BQ 3.0) sham stimulation group:

Device used: Q Therapeutic System (BQ 3.0)

In Stage 1: 45 sessions over a period of 9 weeks (5 treatments per week) of sham study intervention with BQ 3.0 (frequency and intensity parameters will be set to zero so that no stimulation is delivered) including a standardized, pre-defined and evidence-based physical and occupational therapy regimen concurrent with the study intervention.

The BQ 3.0 is a medical device that produces and delivers non-invasive, extremely low intensity and frequency (1-100 Hz.; 0.1-1.0 G), frequency tuned electromagnetic fields in order to stimulate neuronal networks with the aim of reducing disability and promoting neurorecovery. Frequency and intensity parameters will be set to zero so that no stimulation is delivered.

Andre navne:
  • BQ 3.0 Sham-stimuleringsgruppe

The BQ 3.0 is a medical device that produces and delivers non-invasive, extremely low intensity and frequency (1-100 Hz.; 0.1-1.0 G), frequency tuned electromagnetic fields in order to stimulate neuronal networks with the aim of reducing disability and promoting neurorecovery

Andre navne:
  • BQ 3.0 Active Stimulation Group Interventions
Aktiv komparator: BQ 3.0 Active Stimulation Group

Q Therapeutic System (BQ 3.0) active stimulation group:

Device used: Q Therapeutic System (BQ 3.0)

In Stage 1: 45 sessions over a period of 9 weeks (5 treatments per week) of active study intervention with the BQ 3.0 (frequency and intensity parameters will be set to 1-100 Hz.; 0.1-1.0 G), including a standardized, pre-defined and evidence-based physical and occupational therapy regimen concurrent with the study intervention.

The BQ 3.0 is a medical device that produces and delivers non-invasive, extremely low intensity and frequency (1-100 Hz.; 0.1-1.0 G), frequency tuned electromagnetic fields in order to stimulate neuronal networks with the aim of reducing disability and promoting neurorecovery. Frequency and intensity parameters will be set to zero so that no stimulation is delivered.

Andre navne:
  • BQ 3.0 Sham-stimuleringsgruppe

The BQ 3.0 is a medical device that produces and delivers non-invasive, extremely low intensity and frequency (1-100 Hz.; 0.1-1.0 G), frequency tuned electromagnetic fields in order to stimulate neuronal networks with the aim of reducing disability and promoting neurorecovery

Andre navne:
  • BQ 3.0 Active Stimulation Group Interventions

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Change from Baseline in Modified Rankin Scale
Tidsramme: 4 to 21 days following an ischemic stroke to 90-day post-stroke

Proportion of subjects achieving an excellent outcome defined as a Modified Rankin Scale (mRS) score of 0-1 at the 90-day post-stroke assessment, reflecting freedom from disability.

4 to 21 days following an ischemic stroke to 90-day post-stroke

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Ordinal shift-analyse af mRS (trichotomiseret ved 0-1, 2, 3-6) (Key Secondary Effectiveness Endpoint)
Tidsramme: baseline til 90-dages vurdering efter slagtilfælde
baseline til 90-dages vurdering efter slagtilfælde
Ordinal shift-analyse af mRS (4 niveauer ved 0, 1, 2, 3-6) fra 90-dages vurdering efter slagtilfælde til 180 dages vurdering efter slagtilfælde, inden for dem i den aktive gruppe, som fortsatte med at modtage behandlinger i Etape 2
Tidsramme: fra 90 dages vurdering efter slagtilfælde til 180 dages vurdering efter slagtilfælde
fra 90 dages vurdering efter slagtilfælde til 180 dages vurdering efter slagtilfælde
Change from Baseline in Modified Rankin Scale (Key Secondary Effectiveness Endpoint)
Tidsramme: baseline (4-21 days post-stroke) to 90 days post-stroke

To show that the BQ therapy is effective in reducing disability levels

baseline (4-21 days post-stroke) to 90 days post-stroke
Proportion of subjects achieving functional independence (mRS score of 0-2) (Key Secondary Effectiveness Endpoint)
Tidsramme: at the 90-day post-stroke assessment

To show that the BQ therapy is effective in achieving functional independence.

at the 90-day post-stroke assessment
Stroke Impact Scale Hand Domain (Lead Secondary Endpoint)
Tidsramme: baseline (4 to 21 days following an ischemic stroke) to 90-day post-stroke

Patient reported hand function - To show that the BQ therapy is effective in improving upper limb impairment and function

baseline (4 to 21 days following an ischemic stroke) to 90-day post-stroke
Stroke Impact Scale 16
Tidsramme: baseline (4 to 21 days following an ischemic stroke) to 90-day post-stroke

Patient-reported physical function - To show that the BQ therapy is effective in improving physical function

baseline (4 to 21 days following an ischemic stroke) to 90-day post-stroke
10-meter Walk Test
Tidsramme: change from baseline to 90 days post-stroke

The Functional Ambulation Categories (FAC) will be collected concurrent to the 10MWT to assess the level of independent ambulation.

change from baseline to 90 days post-stroke
Box and Block Test
Tidsramme: baseline (4 to 21 days following an ischemic stroke) to 90-day post-stroke

Arm motor function - To show that the BQ therapy is effective in improving Arm motor function

baseline (4 to 21 days following an ischemic stroke) to 90-day post-stroke
Evaluation of 5-level EQ-5D
Tidsramme: At 90-days post-stroke

Health-related quality of life - To show that the BQ therapy is effective in achieving health-related quality of life (HRQoL)

At 90-days post-stroke
Fugl-Meyer Assessment for Upper Extremity (FMA-UE)
Tidsramme: baseline (4 to 21 days following an ischemic stroke) to 90-day post-stroke

upper limb impairment - To show that the BQ therapy is effective in achieving reducing upper limb impairment, and improving upper limb function

baseline (4 to 21 days following an ischemic stroke) to 90-day post-stroke
Nine-Hole Peg Test
Tidsramme: change from baseline to 90-days post-stroke

finger dexterity - To show that the BQ therapy is effective in achieving reducing upper limb impairment, and improving upper limb function

change from baseline to 90-days post-stroke
The proportion of subjects within those in the active group who continued to receive treatments in Stage 2, achieving an excellent outcome (defined as a mRS of 0-1) at the 180-day post-stroke assessment.
Tidsramme: at the 180-day post-stroke assessment

To show, within those in the active group who continued to receive treatments in Stage 2, that the BQ therapy is effective in attaining freedom from disability, as well as reducing global disability, at 6 months post-stroke in disabled patients when initiated 4 to 21 days following an ischemic stroke.

at the 180-day post-stroke assessment
The proportion of patients within those in the active group who continued to receive treatments in Stage 2, who achieved an excellent outcome defined as a mRS score of 0-1 at the 90-day post-stroke assessment and had an mRS >1 at 180-day post-stroke
Tidsramme: at 180 days post-stroke

To show, within those in the active group who continued to receive treatments in Stage 2, that the BQ therapy is effective in attaining freedom from disability, as well as reducing global disability, at 6 months post-stroke in disabled patients when initiated 4 to 21 days following an ischemic stroke

at 180 days post-stroke
The proportion of patients within those in the active group who continued to receive treatments in Stage 2, who achieved an excellent outcome defined as mRS score of 0-1 at the 180-day post-stroke assessment and had an mRS >1 at 270 days post-stroke.
Tidsramme: at 270 days post-stroke

To show, within those in the active group who continued to receive treatments in Stage 2, that the effect attained in obtaining freedom from disability, as well as reducing global disability, is maintained at 6- and 9- months post-stroke in disabled patients with upper limb motor impairment when initiated 4 to 21 days following an ischemic stroke.

at 270 days post-stroke
The proportion of patients who improved by at least 1 level on the mRS from the 90-day post-stroke assessment to 180-day post-stroke assessment, within those in the active group who continued to receive treatments in Stage 2.
Tidsramme: from the 90-day post-stroke assessment to 180-day post-stroke assessment

To show, within those in the active group who continued to receive treatments in Stage 2, that the BQ therapy is effective in attaining freedom from disability, as well as reducing global disability, at 6 months post-stroke in disabled patients when initiated 4 to 21 days following an ischemic stroke

from the 90-day post-stroke assessment to 180-day post-stroke assessment
The proportion of subjects within those in the sham group who continued to receive treatments in Stage 2, achieving an excellent outcome (defined as a mRS of 0-1) at the 180-day post-stroke assessment, and had an mRS >1 at 90 days post-stroke.
Tidsramme: from the 90-day assessment to the 180-day assessment

To show, within those in the sham group who continued to receive treatments in Stage 2 that the BQ therapy is effective in attaining freedom from disability, as well as reducing global disability, at 6 months post-stroke in disabled patients when initiated 90 days following an ischemic stroke

from the 90-day assessment to the 180-day assessment

Andre resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Serious procedure or device related adverse events & device deficiencies
Tidsramme: Through study completion, an average of 90 ± 15 days post-stroke

To characterize the safety profile of the BQ therapy and to show that the BQ 3.0 performs reliably.

Through study completion, an average of 90 ± 15 days post-stroke
Change in Montreal Cognitive Assessment (global cognitive function)
Tidsramme: at 90-day post-stroke

To show that the BQ therapy is effective in reducing cognitive impairment, at 3 months post-stroke, when initiated 4 to 21 days following an ischemic stroke.

at 90-day post-stroke
Change in Patient Health Questionnaire-8 (depression)
Tidsramme: at 90-day post stroke

To show that the BQ therapy is effective in reducing depression, at 3 months post-stroke, when initiated 4 to 21 days following an ischemic stroke.

at 90-day post stroke
Academic Medical Center Linear Disability Scale (granular level of disability)
Tidsramme: At 90 days post stroke

To show that the BQ therapy is effective in reducing fine-grained level of disability at 3 months post-stroke

At 90 days post stroke
Proportion of subjects achieving functional independence (modified Rankin Scale score of 0-1)
Tidsramme: at 45 days post-stroke

To show that the BQ therapy is effective in increasing functional independence at 1.5 months post-stroke

at 45 days post-stroke
Zarit Burden Interview
Tidsramme: at midterm, 90 days post-stroke, 180 days post-stroke, and 270 days post-stroke.

To formally evaluate the cost-effectiveness of the BQ therapy via caregiver burden.

at midterm, 90 days post-stroke, 180 days post-stroke, and 270 days post-stroke.
Formal cost-effectiveness analysis over a lifetime horizon from the perspective of the United States healthcare system.
Tidsramme: will be assessed at MidTerm (45 Day ± 4 days post- stroke) , Day-90 and D-180 post stroke

To formally evaluate the cost-effectiveness of the BQ therapy over a lifetime horizon from the perspective of the United States healthcare system

will be assessed at MidTerm (45 Day ± 4 days post- stroke) , Day-90 and D-180 post stroke
Relationship between adherence to treatment as measured by the Qompass and the clinical outcomes.
Tidsramme: Will be assessed upon data base lock

To explore the relationship between adherence to treatment as measured by the Qompass and clinical outcomes.

Will be assessed upon data base lock
The proportion of patients within those in the sham group who continued to receive treatments in Stage 2 who improved from the 90-day assessment to 180-day and the improvement was maintained at 270 days post-stroke
Tidsramme: At 180 days post stroke and 270 days post-stroke

To show, within those in the sham group who continued to receive treatments in Stage 2 that the BQ therapy is effective in improving functional independence at 6 months post-stroke, when initiated 90 days following an ischemic stroke.

At 180 days post stroke and 270 days post-stroke

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Efterforskere

  • Studiestol: Jeffrey L. Saver, MD, Coordinating PI
  • Ledende efterforsker: Joel Stein, MD, Coordinating PI

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

20. august 2024

Primær færdiggørelse (Faktiske)

26. december 2025

Studieafslutning (Faktiske)

7. april 2026

Datoer for studieregistrering

Først indsendt

16. april 2024

Først indsendt, der opfyldte QC-kriterier

24. april 2024

Først opslået (Faktiske)

26. april 2024

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

19. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

16. november 2026

Sidst verificeret

1. oktober 2026

Mere information

Begreber relateret til denne undersøgelse

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

IPD-planbeskrivelse

will be shared following site level approval

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ja

produkt fremstillet i og eksporteret fra U.S.A.

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner